In 2012, a six-year-old named Emily Whitehead was sent home from a hospital to die. Standard chemotherapy had failed her leukemia twice, and there was nothing left on the shelf. Her parents chose an experimental infusion of her own re-engineered immune cells instead. Thirteen years later, Emily is cancer-free, and the treatment that saved her, CAR T-cell therapy, has since reached more than 40,000 patients worldwide.
Stories like hers are why gene and cell therapy moved from laboratory concept to clinical reality faster than almost any other area of modern medicine. But one patient’s outcome is not a guarantee for the next. These are documented results for specific patients under specific treatments, not universal promises, and that distinction matters throughout everything that follows.
The Moment Gene Therapy Became More Than a Laboratory Concept
Gene therapy, broadly, means treating disease by changing a patient’s genetic material or the cells carrying it, rather than only managing symptoms with a drug. That can mean supplying a working copy of a missing gene, modifying a patient’s own cells outside the body, or editing DNA directly.
The idea dates to the 1970s and stumbled badly in its early decades, including a fatal 1999 gene therapy trial that set the field back for years. It re-emerged gradually through the 2010s as safer delivery methods, particularly modified viruses, made the approach workable. By 2024, the FDA had licensed more than 40 cellular and gene therapy products, and industry investment topped $10.9 billion in just the first half of that year.
Story One: Treating a Disease by Supplying a Missing Genetic Function
Zolgensma (onasemnogene abeparvovec) treats spinal muscular atrophy (SMA), a genetic disease in which infants lack a working copy of the SMN1 gene, needed for motor neuron survival. Without treatment, the most severe form is typically fatal in infancy.
Approved by the FDA in 2019 for children under two, Zolgensma delivers a functional SMN1 gene through a single intravenous infusion using a modified virus as a carrier. In the pivotal trial, infants treated before symptoms became severe were able to sit, and in some cases stand or walk, milestones essentially unreachable for untreated infants with the most severe form of the disease.
It remains one of the most expensive drugs in the world, priced above $2 million per dose, a fact that shapes who can access it as much as the biology does.
Story Two: When a Patient’s Own Cells Become the Treatment
CAR T-cell therapy does not add a gene to fix a defect. It takes a patient’s own T cells, genetically modifies them in a lab to recognize and attack cancer cells, expands them into the billions, and infuses them back into the patient.
Kymriah (tisagenlecleucel), approved in 2017, was the therapy Emily Whitehead received. At Children’s Hospital of Philadelphia, more than 90% of patients treated for relapsed acute lymphoblastic leukemia go into remission after CAR T-cell therapy, and roughly half of those remain cancer-free long-term. Before CAR T existed, only about 9% of patients with relapsed disease stayed cancer-free.
The treatment carries real risks, most notably cytokine release syndrome, a sometimes severe immune reaction to the flood of activated T cells. Managing that reaction, discovered in part through Emily’s own case, is now standard practice at cell therapy centers worldwide.
Story Three: Gene Editing Changes the Treatment Conversation
Casgevy (exagamglogene autotemcel) is the first FDA-approved therapy built on CRISPR-Cas9 gene editing, cleared in December 2023 for sickle cell disease and later for beta-thalassemia.
Unlike Zolgensma, which adds a gene, Casgevy edits a patient’s own stem cells to switch on fetal hemoglobin production, which compensates for the defective adult hemoglobin that causes sickle cell disease. In the pivotal trial published in the New England Journal of Medicine, 29 of 30 evaluable patients, 97%, were free of severe vaso-occlusive crises for at least 12 consecutive months, and all 30 were free of related hospitalizations. Longer follow-up presented at the American Society of Hematology’s 2025 meeting showed most patients remained crisis-free for an average of more than two and a half years, with some passing the five-year mark.
Treatment is intensive. It requires chemotherapy to clear existing bone marrow before the edited cells are infused, weeks of hospitalization, and specialized treatment centers, a very different experience from a single outpatient infusion.
What These Stories Have in Common, and Where They Differ
| Zolgensma | Kymriah (CAR T) | Casgevy | |
|---|---|---|---|
| Disease | Spinal muscular atrophy | Relapsed leukemia/lymphoma | Sickle cell disease, beta-thalassemia |
| Genetic target | Missing SMN1 gene | Patient’s own T cells (not edited genome) | Edited hematopoietic stem cells |
| Mechanism | Gene addition via viral vector | Cell engineering, no DNA editing of the disease gene | CRISPR-Cas9 gene editing |
| Typical patient age | Infants under 2 | Children and adults | Ages 12 and older |
| Treatment setting | Single IV infusion | Infusion after cell collection and lab processing | Weeks of hospitalization, prior chemotherapy |
| Outcome measured | Motor milestones | Remission rate | Freedom from crises |
| Follow-up shown here | Trial-period results | Up to 13 years | Up to 5 years |
| Key remaining risk | High cost, unknown very long-term durability | Cytokine release syndrome | Chemotherapy conditioning, treatment burden |
What Gene Therapy Can Actually Change
Depending on the disease, a successful gene or cell therapy might prevent disease progression, restore a missing biological function, eliminate the need for regular transfusions, or shift survival expectations that were previously grim. For sickle cell disease, that means measurable freedom from painful crises. For SMA, it can mean the difference between never sitting up and walking independently. For certain leukemias, it can mean durable remission where none existed before.
The word “cure” gets used loosely in coverage of this field. Clinicians treating Emily Whitehead were still hesitant to use it even a decade after her treatment, preferring to track sustained remission year by year. That caution is worth carrying into how any single outcome is read.
The Part Success Stories Can Hide
Behind each highlighted outcome sits a less publicized set of facts: serious adverse events do occur, not every patient responds, and long-term durability is still being established for newer therapies. Roughly half of CAR T patients who achieve remission eventually relapse. Manufacturing a patient-specific cell therapy takes weeks and can fail for some patients. Gene editing therapies require intensive pre-treatment conditioning that itself carries risk.
One patient’s documented result establishes what happened for that patient under trial conditions. It does not establish population-wide effectiveness, which is why regulatory approval depends on data from dozens or hundreds of patients, not a single story.
Why Access and Cost Matter as Much as the Science
A treatment that works is not the same as a treatment that reaches patients. Gene and cell therapies require specialized treatment centers, cold-chain logistics, and highly trained staff, which concentrates access in a small number of major medical centers. Prices commonly run into the hundreds of thousands or millions of dollars per patient, and insurance coverage, eligibility criteria, and geography all determine who can realistically receive treatment. Globally, access skews heavily toward wealthier health systems, leaving many patients with the disease but not the infrastructure to reach the therapy.
What Comes Next for Gene Therapy
The pipeline extends well beyond the three examples here, into inherited eye disease, hemophilia, certain metabolic disorders, and additional cancers, alongside continued research into gene editing precision and safety. Not everything in a clinical trial becomes an approved therapy, and readers evaluating a new headline should check whether a treatment is FDA-licensed or still in trials, information the FDA maintains in its public list of approved cellular and gene therapy products.
Researchers are also working to bring the manufacturing timeline down. Patient-specific cell therapies like Kymriah currently take several weeks to produce, a delay that can matter enormously for patients with rapidly progressing cancers. Newer “off-the-shelf” cell therapy approaches, which use donor cells engineered in advance rather than a patient’s own, are in earlier stages of development and could eventually shorten that wait, though none has yet matched the track record of the personalized approach.
The throughline across Zolgensma, Kymriah, and Casgevy is not that gene therapy fixes everything. It is that for specific, well-defined genetic diseases, modifying the underlying biology rather than only managing its symptoms has produced outcomes that were not achievable a generation ago, for patients who often had no other options left.
FAQ
Q: What is gene therapy?
A: Gene therapy treats disease by changing a patient’s genetic material or the cells carrying it, either by adding a functional gene, editing existing DNA, or engineering a patient’s own cells.
Q: Is gene therapy a permanent cure?
A: Some therapies have produced durable, long-term results, such as over a decade of remission in early CAR T patients, but outcomes vary by disease and patient, and clinicians are often cautious about the word “cure” until years of follow-up accumulate.
Q: What diseases can gene therapy treat?
A: Approved therapies currently treat conditions including spinal muscular atrophy, certain leukemias and lymphomas, sickle cell disease, beta-thalassemia, and some inherited eye diseases, with more in clinical trials.
Q: How is gene therapy different from gene editing?
A: Gene therapy is the broad category of treating disease through genetic material. Gene editing, such as CRISPR-Cas9, is one specific method within that category that directly modifies existing DNA rather than adding a new gene copy.
Q: What are the risks of gene therapy?
A: Risks vary by therapy and can include immune reactions like cytokine release syndrome, complications from pre-treatment chemotherapy, and uncertainty about very long-term durability for newer treatments.
Q: How much does gene therapy cost?
A: Costs are substantial, often ranging from several hundred thousand to more than $2 million per patient depending on the therapy, which significantly affects access.
Q: Are gene therapies available to everyone?
A: No. Treatment requires specialized centers, meets specific eligibility criteria, and access is uneven globally and even within wealthier countries due to cost and infrastructure requirements.